Cancer Prevention

Genetic and Genetic Cancer Screening Saves Lives

 
Karen Grinzaid, Assistant Professor of Human Genetics and Executive Director of JScreen, a national online genetic disease screening program based out of Emory University School of Medicine again joins eHealth Radio and the Health News and Technology Channels.
Listen to interview with host Eric Michaels and guest Karen Grinzaid discuss the following:
Tell us about jscreen.org – what you do and what kind of genetic diseases and genetic cancers do you test for?
Tell me first about genetic testing for cancer – are many cancers genetic and if you find you have one what are the options?
Tell us about testing for genetic diseases and again once you find out the information how to best use it?
How does one get tested – explain the process of how to get the test, and the results?
Please just summarize how important and easy it is go get genetic and cancer genetic screening?
Karen Grinzaid is Assistant Professor of Human Genetics and Executive Director of JScreen, a national online genetic disease screening program based out of Emory University School of Medicine. She has extensive experience in genetic counseling and testing, clinical care and clinical research. Karen is proud of JScreen’s success in helping couples across the U.S. have healthy babies and in giving people the information they need to help prevent the devastating effects of hereditary cancer.
Karen received her B.A. in Psychology from Northwestern University and her M.S. in Human Genetics from Sarah Lawrence College. She is certified in Genetic Counseling by the American Board of Medical Genetics/American Board of Genetic Counseling and as a Clinical Research Coordinator through the Association of Clinical Research Professionals.
About JScreen
JScreen is a national non-profit public health initiative dedicated to preventing genetic diseases and cancer common in Jewish and other populations. Headquartered in Atlanta at Emory University School of Medicine, the JScreen initiative provides convenient at-home access to cutting-edge genetic testing technology, patient education, and genetic counseling services. JScreen believes the combination of education, access to premier genetic screening technologies, and personalized, confidential support are the keys to preventing devastating diseases. 
 
 
Website: https://www.jscreen.org  
Social Media Links: Facebook: @MyJScreen Instagram: @GetJScreened Twitter: @MyJScreen
People also listened to this: Pelvic Floor Physical Therapy with Dr. Melanie Carminati

AI-powered technology enabling early detection of serious health diseases

 
 
Jim Kean, the CEO of Molecular You joins eHealth Radio and the Health News and Technology Channels to discuss how their AI-powered technology is enabling early detection of serious health diseases even before symptoms appear.
Listen to interview with host Eric Michaels and guest Jim Kean discuss the following:
What particular problems does Molecular You’s solution solve?
What inspired you to feel passionate about this cause?
How important is AI to what you do?
How do you think this will change the healthcare world?
What would you recommend to listeners who want to be more proactive about their long-term health today?
Jim Kean is the CEO of Molecular You. He is a senior technology executive with an innovative career focused on making healthcare easier by pioneering disruptive consumer-oriented health and wellness digital experiences. The consistent theme: creating user delight, loyalty, and retention while fundamentally re-engineering the cost of delivery.
As the former CEO of WellnessFx™, he provided affordable consumer health services, earning recognition as the 2012 Innovative Company of the Year. Kean also spearheaded online health communities as President of Sapient Health Network, which merged with WebMD in 1999. After WebMD, Jim served as Entrepreneur in Residence with Alloy Ventures of Palo Alto. With a rich history of scaling companies, he continues to lead groundbreaking ventures, most recently as CEO of Molecular You.
 
Website: https://www.molecularyou.com
People also listened to this: Making It Through Your First Holiday Season After a Divorce

Cell-ing the Future: CytoImmune’s CEO Talks About Expanded Role in Cell Therapy

 
Dr. Jose E Vidal who is currently the CEO of CytoImmune Therapeutics, a company at the forefront of a novel natural killer cell therapy for lung cancer, currently in phase 1 clinical trials joins eHealth Radio and the Health News and Cancer Information Channels.
Listen to interview with host Eric Michaels and guest Dr. Jose E. Vidal discuss the following:
What is gene and cell therapy and how does it work?
What conditions can be treated with cell therapy?
What is the difference between treatment therapy and curative therapy?
What is the difference between chemo/radio therapy and immunotherapy for cancer?
When will cell therapy be available to patients? What are the limitations?
In conclusion, cell therapy is the next significant step in fighting hard to treat cancer and autoimmune conditions. It has been proven to provide results superior to any treatment seen before. Now, we are working on improving access for patients by optimizing the manufacturing process and lowering therapy cost.
Dr. Jose Eduardo Vidal obtained his doctoral degree in Cellular and Molecular Biology from the University of Puerto Rico. He started his career in the pharmaceutical industry in Wyeth as a process development scientist working with small molecules and the first Biologics development pipeline upon the acquisition of Immunex.
With Wyeth he worked on the development and commercial launch of Mylotarg (very first ADC). He continued to develop as a biopharmaceutical professional occupying positions of increased responsibility in Tech Services, Process Development and Quality. After 10 years with the company and managing 14 sites world wide Jose joined Amgen as the head of Process Development. With Amgen Jose managed the biologics new product development with over one hundred programs in the pipeline. Jose also managed the drug substance manufacturing organization as the VP of operations and also lead the global late stage product pipeline as the global VP of Process Development where he got acquainted with Cell and Gene therapy.
In 2018 Jose joined Atara where he led the company as SVP of Process Development and Global Quality to develop and submit for commercial licensing the first ever Allogeneic TCell therapy product (Ebvallo) which was approved for commercial distribution in Dec 2022. He also successfully designed and led the development of TCell therapy manufacturing process in stirred tank, perfusion bioreactors.
Lately Jose joined Cytoimmune Therapeutics as the Chief Operations Officer and has been working in starting up the company and the operation from the ground up with operations in PR. Cytoimmune is focused in developing oncology and autoimmune malignancies therapies based on Allogeneic NK-CAR cells.
Jose has also worked with other operations and startups as Pfizer and Biovail and has served as advisor for multiple biotechnology startups with 25 years in the industry in which he has achieved taking from RnD to market more than 200 products/therapies and has pioneered the evolution of therapies from chemical synthesis, biologics to cell and gene therapy. Jose is an early adopter and champion of real time predictive statistical modeling and deep machine learning.
Website: https://www.cytoimmune.com
Social Media Links: Linkedin: https://www.linkedin.com/company/cytoimmune-therapeutics  Twitter: @CytoImmune
People also listened to this: A Breakthrough Solution for Treating Central Nervous System Disorders Including Strokes and Cluster Headaches

Targeted Radiotherapies for Patients with Unmet Needs: A Conversation with Actinium Pharmaceuticals CEO Sandesh Seth

 
 
Sandesh Seth, CEO of Actinium Pharmaceuticals which is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs joins eHealth Radio and the Cancer Information and Health News Channels.
Listen to interview with host Eric Michaels and guest Sandesh Seth discuss the following:
What is unique about Actinium’s radiotherapy approach?
Tell me about Iomab-B, its target population, and how it will affect the patient journey.
Actimab-A is also in AML. How is it different from Iomab-B and what’s the approach here?
What’s next in your pipeline?
Tell me what upcoming catalysts I should expect in the second half of 2023.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an induction and conditioning agent prior to bone marrow transplant, and Actimab-A (National Cancer Institute CRADA pivotal development path), a therapeutic, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. Actinium plans to advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. Actinium's technology platform is the basis for collaborations with Astellas Pharma for solid tumors, AVEO Oncology/LG Chem Life Sciences for HER3 solid tumors, and EpicentRx for its CD47 targeting agent, and several internal programs in solid tumors. Actinium holds more than 200 patents and patent applications.
Website: https://www.actiniumpharma.com
Social Media Links: Linkedin: https://linkedin.com/company/actinium-pharmaceuticals-inc-Facebook: https://facebook.com/people/Actinium-Pharmaceuticals-IncTwitter: https://twitter.com/ActiniumPharma
People also listened to this: The Miracle of Enzymes to Heal Digestive Problems

Biotechnology company developing therapeutic candidates targeting drug-resistant and devastating cancers using ferroptosis

 
 
Randy Milby, the Chief Executive Officer and Chairman of Hillstream BioPharma, a biotechnology company developing therapeutic candidates targeting drug-resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death, and immuno-oncology targeted novel biologics joins eHealth Radio and the Cancer Information & Health News Channels.
Listen to interview with host Eric Michaels and guest Randy Milby discuss the following:
Please tell us a bit about your background and Hillstream BioPharma.
What developments are currently in Hillstream’s pipeline?
How does ferroptosis-targeted therapy differentiate from other cancer treatments currently available or under development?
Why is it important to Hillstream to develop drug resistant therapeutics for cancers with few treatment options?
What advice can you share with industry peers, key opinion leaders, or anyone pursuing R&D in the biotechnology space?
Looking ahead, what exciting advances do you think are on the horizon for Hillstream?
Mr. Milby previously served as Chief Executive Officer and Member of the Board of Directors at CorMedix, a publicly traded biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of inflammatory and infectious diseases. He is a seasoned executive who led the increase in market capitalization from $3M to a peak of $350M of Cormedix while improving the company’s financial position with capital raises from equity markets. He oversaw efforts to gain CE Market approval of Neutrolin® in the European Union and held increasing roles of responsibility at Goldman Sachs and Dupont Merck prior in his career.
 
Website: https://hillstreambio.com 
Social Media Links: Facebook: https://facebook.com/HillstreamBioPharma  Linkedin: https://linkedin.com/company/hillstream-biopharma  Twitter: https://twitter.com/HillstreamB 
People also listened to this: Checkable Medical: Revolutionizing Home Healthcare and Telemedicine

The Opportunity In Cancer: How to Radically Transform Your Cancer Recovery Journey

 
 
Dr. Katrina Cox, the best selling author of "The Opportunity In Cancer: How to Radically Transform Your Cancer Recovery Journey", an international bestseller in four countries across multiple categories joins eHealth Radio and the Cancer Information and Health News Channels.
Listen to interview with host Eric Michaels and guest Dr. Katrina Cox discuss the following:
How does one boost their energy after cancer?

How does someone deal with anxiety and fear after cancer treatment?

Do share if you would how can one create a plan to reduce the chances of cancer recurrence?
How can one become a strong support for a cancer survivor?

Looking at the positive angle on all this - how can someone who has cancer, or has had cancer explore what the opportunity in cancer is when it’s the 2nd leading cause of death globally?
Dr. Katrina Cox is a Naturopathic Doctor, a lover of science, nature, and the human body. As a passionate healthcare practitioner, she’s spent the last decade observing, researching, and connecting with cancer survivors. Witnessing the inspirational journeys of her parents, and patients has allowed her to see the opportunity that cancer presents to each of us. As the author of the international best selling book - The Opportunity in Cancer she hopes to bring awareness and a new framework to explore solutions to the many challenges that cancer survivors and their families face. Ultimately, her goal is to help survivors begin their recovery journey on their own terms, at their own speed and in the comfort of their own homes.
Website: https://theopportunityincancer.com 
Social Media Links: Facebook: https://facebook.com/CancerRemissionMission Instagram: https://instagram.com/thecancerremissionmission 
People also listened to this: Charlie’s Table Gluten Free Pasta Invites Everyone to Eat Together

Dr. John Sylvester of GenesisCare on Prostate Cancer Awareness

 
 
Dr. John E. Sylvester, Radiation Oncologist at GenesisCare, a premier provider in cancer and urology care joins eHealth Radio and the Cancer Information and Health News Channels. With over 300 expert physicians across the U.S., GenesisCare offers advanced technologies and treatments as well as personalized integrated approach to care.
Listen to interview with host Eric Michaels and guest Dr. John E. Sylvester discuss the following:
Considering the staggering statistic that 1 in 8 men will be diagnosed with prostate cancer in their lifetime, is there anything the average person can do proactively to identify prostate cancer and when should they come in for a consultation? Are there any key indicators or high-risk factors people need to know?
What are the biggest challenges people face once diagnosed with prostate cancer, and how can they overcome them?
What do you all do differently at GenesisCare, and what are the benefits for patients? What can other cancer care facilities learn from you?
What are the latest innovations in prostate cancer treatment, and what do you see coming on the horizon that could help people achieve more positive outcomes?
What is most rewarding about the work that you do?
Summary: In 2020, more than 10 million cancer screenings were missed due to the pandemic. The American Association for Cancer Research revealed between March and December 2020, the nation saw an 11 percent increase in patients diagnosed with inoperable or metastatic cancer compared to the same period in 2019.
Dr. John Sylvester has performed over 6,000 prostate brachytherapy procedures. He has developed multiple technical improvements in the procedure, by improving visualization of the urethra during the procedure, optimally utilizing R.A.P.I.D. strand, and co-developed THINStrand. He has published numerous articles and medical textbook chapters on prostate brachytherapy and co-authored and edited The Prostate Cancer Treatment Book. He wrote the white paper on 4-D Calypso image guided IMRT and was the first physician in the US to use SpaceOAR in prostate cancer IG-IMRT. Dr. Sylvester earned the “Innovation Research Award 2014” from the Manatee County Chamber of Commerce and was awarded Sarasota Magazine’s Top Doctors distinction from 2012-2016. He publishes Prostate cancer research papers every year and regularly lectures at the National Radiation Oncology Society Medical Conferences (ASTRO, ABS).
 
 
Website: https://www.genesiscare.com 
Social Media Links: Facebook: https://facebook.com/GenesisCareUS  Linkedin: https://linkedin.com/company/genesiscare  Twitter: https://twitter.com/GenesisCareUS 

JScreen.org saves lives – Give a Spit and get Genetic and Cancer Screenings!

 
 
Karen Grinzaid, Assistant Professor of Human Genetics and Executive Director of JScreen, a national online genetic disease screening program based out of Emory University School of Medicine joins eHealth Radio and the Health News and Technology Channels.
Listen to interview with host Eric Michaels and guest Karen Grinzaid discuss the following:
What is JScreen exactly? How did the service come to be called JScreen?
How did it start – tell us about the couple that came to you in Atlanta and their story about their child and the inspiration behind JScreen?
How does it work for people who want to get Screened?
How does the testing work with your own doctors?
Who helps you understand the results – is there a doctor or Genetic Counselor who talks to you about the screening?
How long from when you order the tests until you receive results?
How many tests can you get at one time? What are the costs?
Since you are a non-profit – can people or groups donate to your organization and how to do so?
Karen Grinzaid is Assistant Professor of Human Genetics and Executive Director of JScreen, a national online genetic disease screening program based out of Emory University School of Medicine. She has extensive experience in genetic counseling and testing, clinical care and clinical research. Karen is proud of JScreen’s success in helping couples across the U.S. have healthy babies and in giving people the information they need to help prevent the devastating effects of hereditary cancer.
Karen received her B.A. in Psychology from Northwestern University and her M.S. in Human Genetics from Sarah Lawrence College. She is certified in Genetic Counseling by the American Board of Medical Genetics/American Board of Genetic Counseling and as a Clinical Research Coordinator through the Association of Clinical Research Professionals.
About JScreen
JScreen is a national non-profit public health initiative dedicated to preventing genetic diseases and hereditary cancer. Headquartered in Atlanta at Emory University School of Medicine, the JScreen initiative provides convenient at-home access to cutting-edge genetic testing technology, patient education and genetic counseling services. JScreen believes the combination of education, access to premier genetic screening technologies and personalized, confidential support are the keys to preventing devastating diseases.
Although both JScreen and direct to consumer DTC companies allow participants to screen at home. JScreen’s program is led by medical professionals at an academic medical center and provides medical grade testing that is used in doctor’s offices, as well as specialized genetic counseling via tele-health.
 
 
Website: https://www.jscreen.org  
Social Media Links: Facebook: @MyJScreen Instagram: @GetJScreened Twitter: @MyJScreen

How Telehealth is Enhancing Patient Care and Health Outcomes

 
 
Michael Gorton, the CEO and founder of Recuro Health and Founding CEO and Chairman of Teladoc joins eHealth Radio and the Healthcare and Health News Channels. Recuro Health is an integrated digital health solution that transitions the U.S. healthcare system from a reactive, disease-focused model to a population health outcomes approach.
Listen to interview with host Eric Michaels and guest Michael Gorton discuss the following:
How did Recuro start?
Tell us more about what Recuro offers as a digital health solutions company?
What makes Recuro different from other digital health companies?
Who are your services available to?
What role will digital health play post-pandemic as patients return to in-person doctor’s appointments?
Can you tell our viewers more about your Covid at-home lab testing kits?
How does digital health enhance healthcare in rural and underserved communities?
Can you speak more on Recuro’s approach to behavioral and mental health? What kind of digital health solutions does Recuro offer?
A quintessential entrepreneur, mentor, and company builder, Michael leads the Recuro Health team which includes several leaders from Teladoc, where he served as the founding CEO and pioneered an industry-changing health care model that created a new efficiency paradigm in healthcare by delivering physicians to patients nationwide in under 12 minutes for $35.
Gorton ran Teladoc as CEO and Chairman for the first seven years of operations. Under his term, the company grew from a concept to one of the most recognized innovations in healthcare, with nearly two million patient members nationwide. Under the Teladoc model, physicians made more and patients paid less. Teladoc was studied and advocated by most of the major healthcare think tanks and was recently named one of the most innovative companies in healthcare. Teladoc recently entered the NYSE and now has a market cap of over $30B.
Michael’s decades of experience as a strategic visionary, impacting the telecommunications, music and healthcare industries include a leadership role as a founder of Principal Solar where he applied his business expertise, scientific education and training to the renewable energy sector -- a strong voice and proponent of solar power.
He has served as a partner of the Texas Acceleration Group (TAG), an entity formed to assist startup companies and participated as a founder of Palo Duro Records. He is also credited as a founder of Internet Global, a company that delivered the first DSL network and one of the first VOIP networks. Prior to this, he worked as a project engineer at Dallas Power & Light dealing with power plants, distribution, transformer management and integration of renewable energy into the grid.
Michael earned a B.S. in engineering from Texas Tech, an M.S. in Physics from the University of Texas at Dallas and a Juris Doctorate from Texas A&M.
Website: https://www.recurohealth.com
Social Media Links: Facebook: https://facebook.com/RecuroHealthLinkedin: https://linkedin.com/company/recuro-healthTwitter: https://twitter.com/RecuroHealth

Plus Therapeutics: Gliblastoma, Rhenium NanoLiposome, and Harnessing the Power of Radiation Therapy

 
 
Dr. Marc Hedrick, President and CEO at Plus Therapeutics which is a clinical-stage pharmaceutical company focused on making a positive impact on patients’ lives and adding value to the healthcare system joins eHealth Radio and the Cancer Information and Health News Channels.
Listen to interview with host Eric Michaels and guest Dr. Marc Hedrick discuss the following:
What is Plus Therapeutics, and what is its mission?
Tell us about your background and what brought you to Plus Therapeutics?
What is Rhenium NanoLiposome (RNL™) and how is it delivered to cancerous brain tumors?
How could RNL help advance current treatment options for GBM and why is this important for patients?
Do you think most people understand radiation and its potential benefits as a cancer therapy?
What do you think is the most common misconception that people hold about radiation as a cancer treatment?
What’s next Plus Therapeutics? Is Plus developing other investigational candidates as part of its broader pipeline?
Dr. Marc Hedrick is the President and CEO at PLUS THERAPEUTICS, Inc. Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc. Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA. Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.
 
 
Website: plustherapeutics.com
Social Media Links: Facebook: facebook.com/plustherapeutics  Instagram: instagram.com/plustherapeutics  Twitter: twitter.com/plustxinc Linkedin: linkedin.com/company/plustherapeutics